Clinical trial for a herbal syrup (named Hero) in reduction of COVID 19 respiratory infection

Clinical trials of a syrup from three medicinal plants with effective index glycyrrhizin index in reducing inflammation, cough, and duration of hospitalization caused by Covid-19

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220830055834N1

Enrollment

Registered

2023-01-25

Start date

2022-12-03

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Infection of COVID-19. COVID-19: confirmed by laboratory testing

Interventions

Intervention 1: Control group: The routine treatment would be given to this group as well as Placebo which would look and taste like the Hero Syrup. Intervention 2: Intervention group: There would be

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 65 years old Proven infection with COVID - 19 Ability (mental and physical ) to use the drug syrup Lack of hypersensitivity to the drug and similar compounds. Ability to respond to contact and interview about the effectiveness of the drug. patient must have not be hospitalized in the ICU ward.

Exclusion criteria

Exclusion criteria: Negative criteria for COVID-19 infection

Design outcomes

Primary

Measure	Time frame
Pressure of Oxygen in the blood. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: Oxymeter for blood oxygen.;Shortness of breath. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: observation for shortage of breath.;Fever. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: Thermometer for fever.;Cough. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: observation of cough.	—

Measure

Time frame

Pressure of Oxygen in the blood. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: Oxymeter for blood oxygen.;Shortness of breath. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: observation for shortage of breath.;Fever. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: Thermometer for fever.;Cough. Timepoint: At the admission time and every hour for the first 12 hours, depending on the severity of symptoms every 1 hour. then twice a day up to the end of the trial. Method of measurement: observation of cough.

—

Secondary

Measure	Time frame
The death rate would be compared in 2 groups of test and control. In the test group, they received Hero Syrup and routine treatment, and in the control group, they received only routine treatment. Timepoint: At the end of 14 days of infection period. Method of measurement: Counting the death of patients in 2 groups according to the hospital report and comparing it.;Counting the patients who were hospitalized in the ICU and the duration of their hospitalization in that ward. Timepoint: from the beginning of the symptoms for 14 days, if the patient needed ICU, the duration of hospitalization in the ward would be recorded according to the hospital record. Method of measurement: Counting the days of hospitalization in the ICU ward according to the hospital record.;Patients who needed Ventilators during the 14 days of clinical COVID-19 infection would be followed, counted, and compared. Timepoint: At the end of 14 days of COVID-19 infection, those patients who needed Ventilators would be followed counted, and compared. Method of measurement: Patients who needed the use of Ventilation would be counted and compared in these 2 groups.;Day(s) of hospitalization in ICU ward, if necessary, would bge compared in two groups. Timepoint: from the beginning of the symptoms for 14 days, if the patient needed ICU, the duration of hospitalization in the ward would be recorded according to the hospital record and compared in the 2 groups. Method of measurement: Counting the days of hospitalization in the ICU ward according to the hospital record and would be compared.;Patients who needed a Ventilator during the 14 days of clinical COVID 19 infection would be followed and days of this requirement would be compared in two groups. Timepoint: At the end of 14 days of COVID-19 infection. Method of measurement: At the end of 14 days of COVID-19 infection, days of used Ventilators by patients would be counted and compared.	—

Measure

Time frame

The death rate would be compared in 2 groups of test and control. In the test group, they received Hero Syrup and routine treatment, and in the control group, they received only routine treatment. Timepoint: At the end of 14 days of infection period. Method of measurement: Counting the death of patients in 2 groups according to the hospital report and comparing it.;Counting the patients who were hospitalized in the ICU and the duration of their hospitalization in that ward. Timepoint: from the beginning of the symptoms for 14 days, if the patient needed ICU, the duration of hospitalization in the ward would be recorded according to the hospital record. Method of measurement: Counting the days of hospitalization in the ICU ward according to the hospital record.;Patients who needed Ventilators during the 14 days of clinical COVID-19 infection would be followed, counted, and compared. Timepoint: At the end of 14 days of COVID-19 infection, those patients who needed Ventilators would be followed counted, and compared. Method of measurement: Patients who needed the use of Ventilation would be counted and compared in these 2 groups.;Day(s) of hospitalization in ICU ward, if necessary, would bge compared in two groups. Timepoint: from the beginning of the symptoms for 14 days, if the patient needed ICU, the duration of hospitalization in the ward would be recorded according to the hospital record and compared in the 2 groups. Method of measurement: Counting the days of hospitalization in the ICU ward according to the hospital record and would be compared.;Patients who needed a Ventilator during the 14 days of clinical COVID 19 infection would be followed and days of this requirement would be compared in two groups. Timepoint: At the end of 14 days of COVID-19 infection. Method of measurement: At the end of 14 days of COVID-19 infection, days of used Ventilators by patients would be counted and compared.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholam Reza Talei

Khoram-Abad University of Medical Sciences

taleireza@gmail.com+63 3120175

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026